RCS - Genflow Biosciences - Company Update on Dog Trials

Genflow BiosciencesAnnouncement

18/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250818:nRSR6062Va&default-theme=true

RNS Number : 6062V  Genflow Biosciences PLC  18 August 2025

 

 

18, August 2025

 

Genflow Biosciences Plc

 

Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No
Adverse Effects Reported

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
the only publicly listed longevity company in Europe, provides an update on
its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating
the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for
age-related decline in elderly dogs.

 

The randomized, controlled trial, conducted with CRO Syngene, involves 28
beagles aged 10+ years. In March, recipients received three different
modalities of SIRT6 gene therapy with no ill or adverse effects, while
controls remain untreated. The dogs will now enter a five-month follow-up
period expected to conclude in January 2026.

 

The strategic goal of this proof-of-concept trial is to generate compelling
preclinical data that will enable a licensing agreement with a leading Animal
Health company. GF-1004 is a first-in-class gene therapy candidate targeting
fundamental aging mechanisms shared by both dogs and humans. By intervening at
the mitochondrial and epigenetic levels, GF-1004 offers the potential to not
only extend lifespan, but also improve the quality of life in companion
animals, a rapidly growing, high-value market segment.

 

Study objectives are to:

1.   Confirm feasibility of GF-1004 administration in the target population.

2.   Validate safety and efficacy at the proposed administered dose.

3.   Demonstrate multi-dimensional benefits relevant to both clinical
outcomes and consumer appeal, including:

o  Reduced biological age (GRIM methylation clock)

o  Increased muscle strength and mass

o  Enhanced mitochondrial function

o  Improved coat quality

o  Better overall health metrics

 

Translational Potential

Since dogs and humans share conserved aging pathways, success in this trial
will provide a strong foundation for expansion into human health applications,
unlocking additional markets in longevity therapeutics.

 

Dr. Eric Leire, CEO of Genflow, commented: "Now that all dogs have received
the treatment without any adverse events, we've taken an important step in
confirming the treatment's safety profile. We are fully focused on advancing
GF-1004 to secure a partnership with an animal health company, combining
scientific and commercial expertise to pave the way for a new class of
therapeutic medicines for dogs. Our shared goal is to extend the healthspan of
dogs, and we believe this study will demonstrate the safety and potential
efficacy of GF-1004 while opening the door to broader applications of our
proprietary platform in age-related diseases in both companion animals and,
ultimately, in humans."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 207 432 0501

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs planned for 2025, include a clinical trial that will explore the
potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZGMRVKNGKZM